Skip to main content
. Author manuscript; available in PMC: 2006 May 9.
Published in final edited form as: Int J Radiat Oncol Biol Phys. 2006 Apr 1;64(5):1482–1494. doi: 10.1016/j.ijrobp.2005.11.045

Fig. 2.

Fig. 2

Dose-dependent TRAIL gene expression specifically suppresses human esophageal adenocarcinoma cells but not in NHLF. A or B, Results of flow cytometry analysis of transgene expression in GFP cell population. Four cell lines were treated with Ad/CMV-GFP or Ad/gTRAIL at MOIs ranging from 0 to 1,000 VP and harvested 2 days after treatment. Levels of GFP in the cells were determined by using FACS. C, Cell viability determined by the XTT assay in different cell lines at the fourth day after treatment with Ad/TRAIL-F/RGD at MOIs ranging from 0 to 5,000 VP. D, Level of TRAIL expression in Seg-1 cells after treatment with different doses of Ad/TRAIL-F/RGD plus/minus radiotherapy, as determined by western blots analysis. β-actin was used as a loading control.